# Longboard Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/longboard-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: www.longboardpharma.com
- Total disclosed funding: $56M
- Latest round: Series A (Oct 27, 2020)
- Investors on record: 5

## About

Longboard Pharmaceuticals, Inc. is a US-based biopharmaceutical company focused on developing innovative therapies for neurological and rare diseases through GPCR-targeted medicines.Founded in 2020 and headquartered in San Diego, US, Longboard Pharmaceuticals specializes in creating treatments for neurological conditions. The company has engaged in three notable deals, with its latest funding round being a PIPE transaction amounting to USD 2.5 billion on October 14, 2024, led by the Lundbeck Foundation. CEO Kevin Lind oversees the company, which has not undergone any significant pivots since its inception.Longboard Pharmaceuticals focuses on developing innovative therapies aimed at treating neurological and rare diseases. The company's main product offerings center around a pipeline of GPCR-targeted medicines, which leverage over 20 years of research in G protein-coupled receptors (GPCRs). These therapies address various aspects of human physiology and are designed to be potentially best-in-class solutions for patients. Longboard's client base includes healthcare providers, research institutions, and pharmaceutical partners, with an emphasis on both clinical and commercial applications. The geographical markets for these products extend beyond the United States, encompassing regions such as Europe and Asia, where there is a growing demand for advanced neurological treatments.Longboard Pharmaceuticals generates revenue primarily through partnerships and collaborations with pharmaceutical companies and research institutions. The transaction structure typically involves agreements for licensing and co-development of its GPCR-targeted drug candidates, which may include milestone payments and royalties based on future sales. While specific pricing details for the therapies are not disclosed, the company’s flagship products are expected to be positioned competitively within the market. Revenue streams are anticipated to arise from both direct-to-consumer and B2B channels, as the company aims to establish its presence in the neurology sector through strategic collaborations and partnerships that facilitate access to its therapies. For the year 2023, Longboard reported an EBITDA of USD -55.78 mn.Longboard Pharmaceuticals plans to leverage its recent PIPE funding of USD 2.5 billion from Lundbeck to enhance its capabilities and accelerate growth. The company aims to expand its product pipeline with new GPCR-targeted therapies, although specific release dates have not been disclosed. Additionally, Longboard is targeting expansion into European and Asian markets, expected to be completed by 2025, to meet the rising demand for its innovative neurological treatments.

## Funding rounds

- Series A, Oct 27, 2020, $56M — T Rowe Price, HBM Partners, Arena Pharmaceuticals, Inc., Cormorant Asset Management, Farallon Capital Management

## Investors

- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series A
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series A
- Arena Pharmaceuticals, Inc. — Series A
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series A
- Farallon Capital Management (https://capitalatlas.ai/funds/farallon-capital-management) — Series A